SYROS PHARMACEUTICALS, INC. Incentive Stock Option Agreement Granted Under 2012 Equity Incentive PlanIncentive Stock Option Agreement • November 20th, 2015 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations
SYROS PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Granted Under 2012 Equity Incentive PlanNonstatutory Stock Option Agreement • November 20th, 2015 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations
SYROS PHARMACEUTICALS, INC. Restricted Stock Agreement Granted Under 2012 Equity Incentive PlanRestricted Stock Agreement • November 20th, 2015 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
SYROS PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTRights Agreement • November 20th, 2015 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT is made as of the 9th day of October, 2014, by and among Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and any Additional Purchaser (as defined in the Purchase Agreement (as defined below)) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH and DANA-FARBER CANCER INSTITUTE, INC. and SYROS PHARMACEUTICALS, INC....Patent License Agreement • November 20th, 2015 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of April 1, 2013 (the “EFFECTIVE DATE”), is among the Whitehead Institute for Biomedical Research (“WHITEHEAD”), a Delaware corporation, having a principal office at Nine Cambridge Center, Cambridge, MA 02142; the Dana-Farber Cancer Institute, Inc. (“DFCI”), a Massachusetts non-profit organization having a principal place of business at 450 Brookline Ave., Boston, MA 02215; and Syros Pharmaceuticals, Inc. (“COMPANY”), a Delaware corporation, having a principal place of business at 480 Arsenal Street, Suite 130, Watertown, MA 02472.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. CANCER LICENSE AGREEMENTCancer License Agreement • November 20th, 2015 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS CANCER LICENSE AGREEMENT (this “Agreement”) dated as of September 11, 2015 (the “Effective Date”) is entered into between TMRC Co., Ltd., a Japanese corporation having a place of business at 1-12-12, Kita Shinjuku, Shinjuku-ku, Tokyo 164-0074, Japan (“TMRC”) and Syros Pharmaceuticals, Inc., a Delaware corporation having a place of business at 620 Memorial Drive, Suite 300, Cambridge MA 02139 USA (“Syros”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. DANA-FARBER CANCER INSTITUTE, INC. and SYROS PHARMACEUTICALS, INC. LICENSE AGREEMENTLicense Agreement • November 20th, 2015 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of February 22, 2013 (the “EFFECTIVE DATE”), is between the Dana-Farber Cancer Institute, Inc. (“DFCI”), a Massachusetts non-profit organization having a principal place of business at 450 Brookline Ave., Boston, MA 02215 and Syros Pharmaceuticals, Inc. (“COMPANY”), a Delaware corporation, having a principal place of business at 1 Memorial Drive, Seventh Floor, Cambridge MA 02142.
